CUE Cue Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CUE

Price (delayed)

$2.23

Market cap

$100.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$59.18M

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the ...

Highlights
CUE's debt is down by 16% year-on-year and by 9% since the previous quarter
The EPS is up by 12% YoY and by 6% QoQ
The gross profit has soared by 114% since the previous quarter but it has dropped by 59% year-on-year
CUE's revenue has surged by 114% since the previous quarter but it has dropped by 59% year-on-year
Cue Biopharma's quick ratio has decreased by 44% YoY and by 9% QoQ
The company's equity fell by 16% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cuebiopharma.com
Peers: OMGA

Key stats

What are the main financial stats of CUE
Market
Shares outstanding
45.12M
Market cap
$100.62M
Enterprise value
$59.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
27.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.49
Earnings
Revenue
$3.82M
EBIT
-$50.64M
EBITDA
-$47.86M
Free cash flow
-$39.52M
Per share
EPS
-$1.2
Free cash flow per share
-$0.85
Book value per share
$0.95
Revenue per share
$0.08
TBVPS
$1.49
Balance sheet
Total assets
$68.89M
Total liabilities
$26.22M
Debt
$16.38M
Equity
$42.67M
Working capital
$40.31M
Liquidity
Debt to equity
0.38
Current ratio
3.34
Quick ratio
3.46
Net debt/EBITDA
0.87
Margins
EBITDA margin
-1,252.7%
Gross margin
100%
Net margin
-1,358.3%
Operating margin
-1,392.1%
Efficiency
Return on assets
-65.9%
Return on equity
-99.1%
Return on invested capital
-201.4%
Return on capital employed
-98%
Return on sales
-1,325.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
-3.04%
1 week
-6.69%
1 month
24.58%
1 year
-42.67%
YTD
-21.75%
QTD
-3.04%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$3.82M
Gross profit
$3.82M
Operating income
-$53.18M
Net income
-$51.89M
Gross margin
100%
Net margin
-1,358.3%
Cue Biopharma's operating margin has plunged by 181% YoY but it has soared by 53% from the previous quarter
CUE's net margin has dropped by 171% year-on-year but it has surged by 53% since the previous quarter
The gross profit has soared by 114% since the previous quarter but it has dropped by 59% year-on-year
CUE's revenue has surged by 114% since the previous quarter but it has dropped by 59% year-on-year

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
2.35
P/S
27.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.49
The EPS is up by 12% YoY and by 6% QoQ
The P/B is 51% below the 5-year quarterly average of 4.9 and 3.2% below the last 4 quarters average of 2.5
The company's equity fell by 16% YoY and by 7% QoQ
CUE's revenue has surged by 114% since the previous quarter but it has dropped by 59% year-on-year
The price to sales (P/S) is 80% lower than the last 4 quarters average of 142.4 and 69% lower than the 5-year quarterly average of 90.4

Efficiency

How efficient is Cue Biopharma business performance
The ROS has shrunk by 170% YoY but it has soared by 53% QoQ
The ROIC has decreased by 42% QoQ and by 33% YoY
Cue Biopharma's return on equity has decreased by 27% YoY and by 3.9% QoQ
The ROA has contracted by 18% YoY and by 2.5% from the previous quarter

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
The total assets is 163% greater than the total liabilities
The current ratio has declined by 45% year-on-year and by 11% since the previous quarter
Cue Biopharma's quick ratio has decreased by 44% YoY and by 9% QoQ
CUE's debt is 62% smaller than its equity
CUE's debt is down by 16% year-on-year and by 9% since the previous quarter
The company's equity fell by 16% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.